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A B S T R A C T
Introduction. Female sexual dysfunction is a current and multifactorial status that greatly affects quality of life.
Menopause, aging, and probably hormonal instability are some of these drastic factors.
Aim. Determine the prevalence of sexual dysfunction in Iranian postmenopausal women and the relationship to
serum status of sex hormones and sex hormone binding globulin (SHBG).
Methods. A total of 149 healthy postmenopausal women aged 43–64, nonhormone therapy user, with intact uterus
and ovaries, enrolled in the cross-sectional study.
Main Outcome Measures. Female sexual function was evaluated by utilizing the Female Sexual Function Index.
Hormonal serum concentration was measured by enzyme-linked Immunosorbent Assay (ELISA). Also, free test-
osterone and free estradiol indexes were calculated. The analysis was performed by using SPSS 16.
Results. Mean age of sample was 52.19  3.76 with 47.48  36.5 month amenorrhea. In the study, 69.8% of women
showed sexual dysfunction in Desire and 61.7% in Arousal, these two being the most affected domains. Lubrication
(49.7%), Pain Domain (45.0%), Orgasm (40.3%), and Satisfaction (36.9%) were in later degree among six assessed
domains. There was no difference between the two groups—with and without dysfunction—in hormone level and
SHBG.
Conclusion. In Iranian postmenopausal women, Desire and Arousal are the most prevalent menopausal sexual
dysfunctions, and Female Sexual Dysfunction is much more than just a hormonal problem. Moghassemi S, Ziaei
S, and Haidari Z. Female sexual dysfunction in Iranian postmenopausal women: Prevalence and correlation
with hormonal profile. J Sex Med 2011;8:3154–3159.
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Introduction
Female sexual dysfunction (FSD) is deﬁned as apersistent or recurring decrease in sexual
desire, persistent or recurring decrease in sexual
arousal, dysparounia, and a difﬁculty or inability to
achieve an orgasm [1]. It is a multifactorial entity
and an underestimated problem with an overall
prevalence of between 20% and 50% [2]. Preva-
lence can change according to the diagnostic cri-
teria used, data collection, and other factors such
as psychological and cultural [3–7], ethical, racial,
and healthy variables between countries [8].
Sexual complaints and problems in women are
prevalent during the entire reproductive life span,
but menopausal women may be more vulnerable
to FSD because of a complex interplay of indi-
vidual factors variably affecting well-being, includ-
ing endocrine changes [9]. Natural menopause
represents a good model to understand the role of
estradiol deprivation in women’s general well-
being, including sexual function. Testosterone (T)
signiﬁcantly declines with age, independently of
the menopausal transition, because of a progres-
sive reduction in adrenal production. However,
the menopausal ovary is still capable of producing
a variable amount of androgens with relevant
effects on women’s health depending on the bio-
availability of sex steroids within target tissues
[10,11]. Most studies of hormones in middle-aged
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women have been done on Caucasian women in
Australia, Europe, North America, and Scandina-
via; thus, little information is available on differ-
ences by ethnicity [12].
Aims
The aim of this study was to determine the preva-
lence of FSD and its possible correlation with the
hormonal proﬁle in healthy postmenopausal
women in Tehran, Iran (Islamic Republic of).
Materials and Methods
We performed a cross-sectional study with endo-
crine measurements. Our survey’s sample were
149 healthy postmenopausal women between the
ages of 43 and 64, who were sexually active (those
who were married and reported having sexual
intercourse in the previous 4 weeks), nonhormone
therapy (HT) users, with intact uterus and ovaries.
We recruited the subjects in a period between
January 1, 2006 and April 20, 2008 at selected
obstetric and gynecologic clinics in Tehran, Fajr
and Avesina hospitals, Aboraihan and Shahid
Haidari polyclinics, and an individual clinic.
The main exclusion criterion taken into account
was the presence of a chronic illness such as dia-
betes mellitus, hyperthyroidism or hypothyroid-
ism, hypertension, smoking and drug abuse,
history of any gynecology-related surgery (except
C-section), and or chemotherapy or radiotherapy.
The Female Sexual Function Index (FSFI) was
completed for all study subjects by interview. The
FSFI is a validated, 19-item, self-administered,
screening questionnaire that measures six aspects
of sexual function (desire, arousal, lubrication,
orgasm, satisfaction, and pain) and is used fre-
quently in research. Each question has six possible
answers that describe the status of sexual function
during the previous 4 weeks. A scoring algorithm
was devised to assess each domain. Score ranges
for all items are 0–5 except for items 1, 2, 15, and
16 (the range is 1–5). The sum score of each
domain multiply in its factor. The full-scale score
range is from 2.0 to 36.0. Therefore, domain
scores less than 3.9 in all six domains are consid-
ered sexual dysfunctions. A total score less than 23
can be considered as FSD. In this study, we used
the Persian version translated by Mohammadi
et al. [13] and its cutoff points. Therefore, a score
<3.3 in the desire domain, score <3.4 in arousal
and orgasm, score <3.8 in satisfaction and pain,
score <3.7 in lubrication, and total score <28 for
FDS total were considered as sexual dysfunction.
A fasting blood sample was taken for all partici-
pants, and hormonal serum concentration includ-
ing total testosterone, estradiol, and sex hormone
binding globulin (SHBG)wasmeasured by ELISA.
Total testosterone was measured in nanogram per
milliliter, estradiol measured in picogram per mil-
liliter by a DRG kit (DRG Instruments GmbH,
Marburg, Germany), and SHBG measured in
nanomole per liter by IBL kit (IBL International,
Hamburg, Germany). On based guidelines in the
DRG kit user manual, the detection limit for test-
osterone is between 0 and 16 ng/mL, sensitivity
0.083 ng/mL, and the within-assay variability
(n = 20, mean [0.73 ng/mL], coefﬁcient of varia-
tion [CV] [4.16%]) [14]. The dynamic range of the
kit for Estradiol ELISA is between 0 and 2,000 pg/
mL, with a sensitivity of 9.714 pg/mL, and the
within-assay variability (n = 20, mean [91.09 ng/
mL], CV [6.81%]) [15].
Based on the Princeton consensus statement on
deﬁnition, classiﬁcation, and assessment [16], total
T and SHBG are one option for clinical assess-
ment of both androgen production and androgen
availability, and the free testosterone index (FTI)
correlates well with free or bioavailable T and can
be used as a substitute. Also, free testosterone and
free estradiol indexes (FEI) were calculated.
Free Testosterone and Free Estradiol Indexes
Calculation of the free androgen index and free
estradiol index (FEI) was carried out using the
following formulas [17,18]:
Total estradiol pg dL
SHBG nmol L
FEI
/ .
/
×
×
⎡
⎣⎢
⎤
⎦⎥ =
0 0367
100
Total testosterone ng dL
SHBG nmol L
FAI
/ .
/
×
× =
0 0347
100
The analysis was performed by using SPSS 16
(SPSS Inc., Chicago, IL, USA).
Main Outcome Measure
Data collection forms included the informed
consent, demographic characteristic, a medical
history survey, and the FSFI.
Result
Table 1 shows the age distribution, menarche age,
marital age, and body mass index of the partici-
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pants. All of the female participants were married
and living with their husbands. The mean age of
the study sample population was 52.19  3.76
with 47.48  36.5 month amenorrhea. Also, 4.1%
of samples were illiterate, 43.9% had received no
more than a primary school education, 41.8% had
attended high school, and 10.1% had graduated
from university. In addition, 83.9% (N = 125)
were householders or unemployed.
In the study, 104 women showed sexual dys-
function in Desire (69.8%; 95% conﬁdence inter-
val [CI], 61.7–77) and 92 (61.7%; CI 95%,
53–69.5) in Arousal, these two being the most
affected domains. Lubrication (49.7%; CI 95%,
41.37–57.96), Pain (45.0%; CI 95%, 36.8–53.32),
Orgasm (40.3%; CI 95%, 32–48), and Satisfaction
(36.9%; CI 95%, 29.16–45.19) were in later
degrees among the six assessed domains. The
mean total FSFI score was 21.13  6.02, while the
proportion of women with FSD based on FSFI
overall scores of 28 or less was 86.6% (CI 95%,
80–91) (Table 2).
Levels of hormones are shown in Table 3. The
mean serum levels of sex hormones and SHBG
were 29.15  28.73(pg/mL) for estradiol,
0.40  0.24 (ng/mL) for testosterone, and
43.76  23.18 (nmol/L) for SHBG.
In order to compare the sex hormone and
SHBG levels with and without FSD, A Mann–
Whitney test was used. No signiﬁcant difference
between the two groups was reported (P > 0.05)
(Table 4).
No correlation existed between hormonal status
(estradiol, testosterone, FTI, and FEI) and FSFI
scores. The Spearman correlation, however, was
signiﬁcant between SHBG and two domains
of FSFI: arousal (correlation coefﬁcient [CC] =
-0.18, P value = 0.043) and orgasm score (CC =
-0.237, P value = 0.007) (Table 5).
Discussion
We assessed the prevalence, and hormonal rela-
tionships, of sexual dysfunction in a sample group
of Iranian postmenopausal women using a vali-
dated study instrument (FSFI). Our study design
had several strengths and weaknesses: (i) This
study was performed in Tehran, and for this
reason, it could not be representative of the situa-
tion in a population from another province; (ii)
Health status is a condition that affects the FSD
risk in women and all women in our study were
considered healthy; (iii) Most sexual function or
dysfunction studies have included a wide age
range, and menopause is an independent variable,
but we focused on healthy postmenopausal women
and assessed the prevalence of FSD and sex hor-
monal status in them.
In this study, the highest prevalence of sexual
dysfunctionwas in the desire domain (69.8%). This
is perhaps a cultural or religious effect: asking or
having interest in sex is perceived negatively; men
must always initiate.Dysfunction in the satisfaction
domain had the lowest prevalence (36.9%). Again, a
cultural component may exist whereby the hus-
band’s preferences and satisfaction aremore impor-
tant than the wife’s; this means that if their partner
was satisﬁed, they are satisﬁed, too.
In results similar to studies by Oksuz and
Malhan [19] and Hassanin et al. [20], the most
prevalent dysfunction domain was desire (69.8%).
Our results are also similar to Beigi et al. that
Table 1 Characteristics of study population
Variable Mean  SD Range
Age (year) 52.19  3.76 43–64
Menarche (year) 13.21  1.53 9–19
Marital age (year) 18.98  4.95 11–42
BMI (kg/m2) 28.58  3.66 18.90–37.78
LMP (month) 47.48  36.5 12–216
BMI = body mass index; SD = standard deviation.
Table 2 Distribution of participant women’s sexual
dysfunction according to domains and total score of FSFI
(N = 149)
Domains
Mean score
 SD
Sexual dysfunction
Present Absent
N % N %
Desire 2.67  0.98 104 69.8 45 30.2
Arousal 2.93  1.23 92 61.7 57 38.3
Lubrication 3.71  1.61 74 49.7 75 50.3
Orgasm 3.52  1.39 60 40.3 89 59.7
Satisfaction 4.26  1.08 55 36.9 94 63.1
Pain 4.02  1.88 67 45 82 55
FSD total 21.13  6.02 129 86.6 20 13.4
FSD = female sexual dysfunction; FSFI = Female Sexual Function Index;
SD = standard deviation.
Table 3 Sex hormone and SHBG levels in
postmenopausal women assessed by ELISA (N = 149)
Hormones Mean  SD Range
Estradiol (pg/mL) 29.15  28.73 0.10–124.00
Testosterone (ng/mL) 0.40  0.24 0.06  1.90
SHBG (nmol/L) 43.76  23.18 1.10  174.00
FEI 0.53  1.81 0.001–15.60
FTI 7.88  33.54 0.41–370.7
FEI = free estradiol indexes; SD = standard deviation; SHBG = sex hormone
binding globulin.
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reported that arousal (75.3%) and desire (62.6%)
are the most prevalent dysfunction domains in
Iranian menopausal women [21].
In our study, prevalence of FSD in healthy post-
menopausal Iranian women was 86.6%. This
ﬁgure is similar to reported FSD in Thai post-
menopausal women not taking HT (82.2%) [22].
In Turkish women (age 45–55), with a similar
culture and ethnicity to Iran, prevalence of FSD
was 67.9% [17], but only 10.2% were menopausal
subjects. Among a survey population of Upper
Egypt, the ﬁgure was 76.9% [20]. In comparison
with sexual dysfunction levels in the United States
(which was 43%), [23] it seems that FSD in
Eastern countries is somewhat higher.
A long-standing population-based study, the
Melbourne Women’s Midlife Health Project,
found a signiﬁcant decrease in women’s desire,
arousal, orgasm, and frequency of sexual activity
and a signiﬁcant increase in vaginal dryness/
dysparounia, with a rate of sexual dysfunction
ranging from 42% to 88% throughout the meno-
pausal transition [24,25].
Despite high prevalence of sexual dysfunction
in postmenopausal women, satisfaction with sexual
relationships was recorded, and such women typi-
cally had a positive attitude toward sexuality [22].
Therefore, common sexual complaints of meno-
pause, such as painful sexual intercourse, low
sexual desire or interest, orgasm, and satisfaction
dysfunctions, should be routinely assessed in clini-
cal practice in order to preserve quality of life
across the aging process [26].
While a marriage duration of greater than
10 years [20], marital status [23], and menopause
[27] are all related to greater FSD, there are some
essentially different characteristics between
women in this study with others. For example,
most of participants were householders, married,
and had a lifetime partner.
Though healthful status is a condition that
reduces the prevalence of FSD [8,28], prevalence
of FSD in our study was rather high, therefore we
could propose greater FSD prevalence in the
general menopausal, nonhealthy, postmenopausal
women and surgical menopause.
From our ﬁndings, there was no relationship
between estradiol and FEI and any aspect of the
FSFI. This may be due to the characteristic of our
survey’s sample who were hypoestrogenic as
mean  SD of estradiol in sample was
29.15  28.73 pg/dL.
Additionally, we could not ﬁnd any relationship
between testosterone, FTI, and FSFI domains.
Table 4 Comparing the Sex Hormone and SHBG Levels with and without FSD (Mannwitni)
Hormone
Domain
Desire Arousal Lubrication Satisfaction Orgasm Pain FSD total
Testosterone Z: -0.366 Z: -0.934 Z: -1.288 Z: -0.245 Z: -0.266 Z: -0.268 Z: -0.732
P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05
Estradiol Z: -0.239 Z: -0.756 Z: -0.078 Z: -1.787 Z: -0.708 Z: -0.905 Z: -1.064
P > 0.05 P > 0.05 P > 0.05 P: 0.074 P > 0.05 P > 0.05 P > 0.05
SHBG Z: -1.406 Z: -1.697 Z: -1.780 Z: -1.165 Z: -1.891 Z: -1.735 Z: -0.549
P > 0.05 P > 0.05 P: 0.075 P > 0.05 P: 0.059 P: 0.083 P > 0.05
FTI Z: -0.594 Z: -0.214 Z: -0.098 Z: -0.613 Z: -1.086 Z: -1.023 Z: -0.411
P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05
FEI Z: -0.587 Z: -0.250 Z: -0.458 Z: -0.836 Z: -1.064 Z: -0.893 Z: -1.172
P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05
FEI = free estradiol indexes; FSD = female sexual dysfunction; SHBG = sex hormone binding globulin.
Table 5 Correlation between Sex Hormone and SHBG Levels with FSFI Scores (Spearman’s rho)
Hormone
Domain
Desire Arousal Lubrication Satisfaction Orgasm Pain FSD total
Testosterone P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05
Estradiol P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05
SHBG P > 0.05 Cc: -0.018 P > 0.05 P > 0.05 Cc:-0.237 P > 0.05 P > 0.05
P: 0.043 P: 0.007
FTI P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05
FEI P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05
FEI = free estradiol indexes; FSD = female sexual dysfunction; SHBG = sex hormone binding globulin.
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This may be because of the hormone assay method
and low range of hormones in postmenopausal
women, especially testosterone. A speciﬁc research
priority area is to develop sensitive and reliable
assays for total and free testosterone measurement
in the lower ranges of normal for women [16].
One limitation in this study is that the gold
standard method “equilibrium dialysis” for bio-
available T in women special in this study, post-
menopausal women who had low range of
estradiol, was not employed. Also, as mentioned by
Davis [27], a single serum testosterone level could
not be representative of testosterone over time in
postmenopausal women. However, there is no evi-
dence that supports the idea that low serum test-
osterone level distinguishes women with FSD
from others.
Second, most studies reporting effects of sex
hormones on sexual function used testosterone
and/or estradiol in pharmacological dosages, which
seemed to be different from intrinsic hormones.
Another supposition is that behavior, ethnicity,
cultural, and religious differences are all more sig-
niﬁcant determining factors than hormone diver-
sity. Unfortunately, there is little data about FSD
and its determinant in menopausal women.
Despite such high levels of FSD prevalent in
Iranian postmenopausal women, there are few sex
clinics in Iran and little discussion about sex func-
tion with patients.
Conclusion
Our ﬁndings suggest that FSD in a female Iranian
menopausal population is more prevalent than
previously reported levels in the literature. Clini-
cians, consequently, must routinely raise questions
about sex with menopausal women.
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